Feb 11 (Reuters) - Seattle Genetics Inc:
* SEATTLE GENETICS AND ASTELLAS ANNOUNCE UPDATED RESULTS FROM PHASE 1B/2 TRIAL OF PADCEV™ (ENFORTUMAB VEDOTIN-EJFV) IN COMBINATION WITH IMMUNE THERAPY PEMBROLIZUMAB AS INVESTIGATIONAL FIRST-LINE TREATMENT FOR ADVANCED BLADDER CANCER
* SEATTLE GENETICS - AFTER MEDIAN FOLLOW-UP OF 11.5 MONTHS, 73% OF PATIENTS HAD CONFIRMED TUMOR RESPONSE WITH MAJORITY OF RESPONSES STILL ONGOING
* SEATTLE GENETICS INC - NO NEW SAFETY SIGNALS OBSERVED FOR COMBINATION Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.